AstraZeneca presents updated data on its vaccine against Covid-19 to the American Data Safety Monitoring Board. The information provided shows that it is 76% effective in stopping symptomatic disease and 100% effective in preventing severe infection. This is what we read in a note from AstraZeneca.
The data are “in line with the interim analysis and confirm that the vaccine is effective in adults, including those over 65,” says AstraZeneca, reiterating its intention to apply for emergency authorization to the FDA. AstraZeneca presented vaccine data on March 21 but was deemed out of date.
The updated data therefore show that the vaccine is less effective than the previous analysis: it is 76%, compared to 79% of the results presented previously. The delivery of updated data to the American authorities follows the controversy of the last few days. In fact, AstraZeneca had presented on March 22 the results of its experimentation conducted on over 30 thousand volunteers in the USA, Chile and Peru: the data showed the efficacy of the vaccine against Covid at 79% in stopping the symptomatic disease and did not raise doubts about its safety. But 24 hours later, the US authorities had voiced the possibility that obsolete information had been included in the results. AstraZeneca therefore undertook to provide more up-to-date data than those presented, which dated before February 17.
“The vaccine is probably very good – Fauci said in an interview with Abc – but the press release released by the company was not entirely accurate and could be misleading”. Data provided by AstraZeneca is from before February 17 They may not take into account the spread of variants of the virus, which is likely to cause the vaccine to be less effective.
.